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Previous estimates of whether long-term exposure to benzodiazepines increases dementia risk are conflicting
and are compromised by the difficulty of controlling for confounders and by reverse causation. We investigated
how estimates for the association between benzodiazepine use and later dementia incidence varied based on
study design choices, using a case-control study nested within the United Kingdom’s Clinical Practice Research
Datalink. A total of 40,770 dementia cases diagnosed between April 2006 and July 2015 were matched on age,
sex, available data history, and deprivation to 283,933 control subjects. Benzodiazepines and Z-drug prescriptions
were ascertained in a drug-exposure period 4–20 years before dementia diagnosis. Estimates varied with the inclu-
sion of new or prevalent users, with the timing of covariate ascertainment, and with varying time between exposure
and outcome. There was no association between any new prescription of benzodiazepines and dementia
(adjusted odds ratio (OR) = 1.03, 95% confidence interval (CI): 1.00, 1.07), whereas an inverse association was
observed among prevalent users (adjusted OR = 0.91, 95% CI: 0.87, 0.95), although this was likely induced by
unintentional adjustment for colliders. By considering the choice of confounders and timing of exposure and covari-
ate measurement, our findings overall are consistent with no causal effect of benzodiazepines or Z-drugs on
dementia incidence.
benzodiazepines; bias (epidemiology); case-control studies; dementia; risk
Abbreviations: ATC, Anatomical Therapeutic Chemical; CI, confidence interval; CPRD, Clinical Practice Research Datalink; DDD,
defined daily dose; DEP, drug exposure period; OR, odds ratio
Dementia prevention is a public health priority. More than
152 million people are expected to be living with dementia by
2050. Dementia is recognized as a leading cause of disability,
is the fifth most important cause of death, and has a global eco-
nomic cost of US$1 trillion (1, 2). There is no curative or disease-
modifying treatment for dementia, increasing the importance of
identifying its risk factors (3). Authors of several studies have
suggested that long-term benzodiazepine use could increase
dementia risk (4). If true, this is an important opportunity to pre-
vent dementia, because 9% of older US adults currently use ben-
zodiazepines, with 31%of these being long-term users (5, 6).
Benzodiazepines, including diazepam (Valium; Hoffmann-
La Roche Inc, Little Falls, New Jersey) and alprazolam (Xanax;
Pfizer Inc, New York, New York) are the most commonly pre-
scribed sedatives and are typically used for insomnia or anxiety.
Despite years of guidance advising against long-term benzodi-
azepine use, because of adverse effects, addiction, and toler-
ance (7), there has been no decline in their use in the past
decade in the United States (8–10), whereas a small decline in
the United Kingdom has been accompanied by greater use of
benzodiazepine-related drugs, including zopiclone, (e.g., Lunes-
ta; Sunovion Pharmaceuticals Inc.Marlborough,Massachusetts),
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zolpidem (e.g., Ambien; Sanofi-Aventis U.S. LLC, Bridgewater,
New Jersey), and zaleplon (e.g., Sonata; Wyeth Pharmaceuticals
Inc., Philadelphia, Pennsylvania), collectively known as Z-drugs
(11).
Benzodiazepines and Z-drugs have dose-related effects on
memory and other aspects of cognitive function (12, 13). How-
ever, no biological mechanism has been demonstrated to under-
lie any link to dementia incidence. Although increased risks of
dementia with long-term benzodiazepine use (14–16) have been
suggested on the basis of studies using insurance records and epi-
demiologic cohort studies, no association was noted in other
recent studies (17, 18). These conflicting results may reflect gen-
uine differences across populations, or different study designs,
availability and use of covariate data, or analysis parameters,
such as minimum time lag between exposure and outcomes (19,
20).
It is not practical or ethical to randomly assign patients to
receive benzodiazepine treatment to estimate harms; there-
fore, observational studies are central to addressing this im-
portant question. Individual, patient-level data sets exist that
include detailed histories of benzodiazepine use going back
years or decades, details of diagnoses and treatment for cog-
nitive disorders, and records of many possible confounding
variables for this relationship. However, several factors com-
plicate any analysis. Benzodiazepine treatment often is initi-
ated before records for a patient begin, precluding the use of
the “new-user” design (21). This is particularly true for those
with very long-term use, who may be most at risk (22). Second,
the main indications for benzodiazepines—anxiety and sleep
disturbance—are both risk factors for and prodromal symptoms
of neurodegenerative disease that may occur many years before
dementia diagnosis, necessitating a lag period to avoid proto-
pathic bias (4). Furthermore, dates associated with diagnoses in
electronic health records may reflect the time of the underlying
event. Together, these factors make the theoretical identification
of confounding from mediating or colliding variables, as is often
suggested (23, 24), difficult. This is important because valid
causal inference relies on the correct identification of and control
for confounders (i.e., variables that are common causes of both
the exposure and the outcome), but conditioning on mediators
(i.e., variables on the causal pathway from exposure to outcome)
or on colliders (i.e., common consequences of the exposure and
the outcome) will introduce bias rather than reduce it (25).
Case-control studies, in which exposures within an exposure
period are compared between cases of a disease and matched
controls, are often used for estimating the associations between
multiple complex exposures and a single outcome. Case-control
studies are used particularly when tackling rare adverse events or
adverse events that may only become apparent after long-term
exposures. However, selection based on outcome rather than ex-
posure status further complicates the ascertainment of confoun-
ders. Clearly, it is optimal to measure potential confounders at
treatment initiation (20), but because cases and controls are not
matched on exposure, the presence of treatment or time of treat-
ment initiation will vary within a matched set. Hence, it is diffi-
cult to know when to optimally ascertain and encode covariates.
Measuring covariates recorded only up to the start of an exposure
window (possibly years before exposure) risks missing confoun-
ders and omitted variable bias, whereas including covariates re-
corded during or after the exposure window (hence, after the
exposure) risks underestimation through unintended adjustment
formediators or colliders (26).
We conducted a case-control study nested within an elec-
tronic health record data set as part of a wider project estimat-
ing the associations of drug use on dementia incidence (27),
and we have explored several of these issues. We present es-
timates for the association between benzodiazepine and Z-
drug prescription and dementia incidence, and explore how
these depend on 1) the inclusion or exclusion of prevalent
users, 2) the timing of covariate ascertainment, and 3) the
minimum lag between treatment and dementia incidence.
Finally, we explore the role of specific covariates and impli-
cations for the conduct and interpretation of future similar
studies.
METHODS
The study was approved by the Independent Scientific Advi-
sory Committee for the Clinical Practice Research Datalink
(CPRD) research (protocol no. 15_056R) andwas registered on
the European Network of Centers for Pharmacoepidemiology
and Pharmacovigilance e-register of studies (register no. EU-
PAS8705). This manuscript has been prepared according to the
Reporting of Studies Conducted Using Observational Rou-
tinely Collected Data guidelines (28). Code lists for the out-
come and covariates are available on request.
Study population and data
CPRD consists of anonymized electronic health records of
17 million patients from 719 general practices and is represen-
tative of age, sex, and ethnicity of the United Kingdom popu-
lation (29). Available data include basic demographics and
coded details of consultations, diagnoses, reported symptoms,
drug prescriptions, referrals to specialist services, and labora-
tory test results.
Selection of case patients and control subjects
All cases of dementia recorded in CPRD were indexed at
the first mention of dementia as a diagnosis or symptom (see
Web Table 1 (available at https://academic.oup.com/aje) for
complete Read code list) or the first prescription of a demen-
tia drug (i.e., memantine, donepezil, rivastigmine, galanta-
mine, or tacrine) if it was followed by a dementia diagnosis
code within 12 months.
Case patients were included in the current study if their index
date occurred between April 2006 and July 2015 and the patient
was aged between 65 and 99 years on that date. Case patients
were excluded if the date of diagnosis was unknown, they had
less than 6 years of “up-to-standard” data history before the index
date, or had any record of motor neuron disease, human immu-
nodeficiency virus infection, acquired immune deficiency syn-
drome, multiple sclerosis, Down syndrome, or alcohol abuse.
For each case, up to 7 control subjects without dementia at
the index date were randomly selected and matched on sex,
year of birth (within 3 years), years of available up-to-standard
data history, and index of multiple deprivation quintile. The
index of multiple deprivation is a weighted sum of indicators of
housing, employment, income, education, living environment,
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and crime for each neighborhood (30). We used incidence den-
sity sampling to select control subjects, hence case patients
could also be selected as control subjects up to the date of meet-
ing case criteria.
Exposure assessment
We defined a drug-exposure period (DEP) for each case/con-
trol group as the period starting after 1 year of up-to-standard
data recorded, and at most 20 years before the index date, and
ending 4 years before the index date (Web Figure 1) (31). This
4-year lag reduces the risk of protopathic bias, because the use
of benzodiazepines in this period may be a marker of undiag-
nosed dementia (32).
For all patients, we obtained details of all drugs prescribed
before the index date. Our primary exposures were the number
of defined daily doses (DDDs) prescribed for benzodiazepines
(World Health Organization Anatomical Therapeutic Chemical
(ATC) categoryN05BA,N05CD, orN03AE) and benzodiazepine-
related drugs (i.e., Z-drugs; ATCN05CF) during the DEP. The
DDD is the assumed average maintenance dose per day for a
drug based on its main indication in adults; we used the DDD
values assigned by the World Health Organization’s Collabo-
rating Center for Drug StatisticsMethodology.
We defined “new users” of benzodiazepines as those pre-
scribed benzodiazepines during the DEP but with no benzodi-
azepine prescriptions in the 12 months before the DEP, and
“prevalent” benzodiazepine users as those prescribed benzo-
diazepines within both the DEP and the 12 months prior (Web
Figure 1). New and prevalent users of Z-drugs were defined
similarly.
Covariates
Potential confounders were identified as any known or
suspected risk factors for dementia (3, 33) or predictors of
benzodiazepine initiation (34, 35). Each covariate was ascer-
tained first using only the patient record up to the start of the
DEP and second using the patient record up to the end of the
DEP.
The following covariates were measured as binary vari-
ables reflecting any history of a diagnosis: diabetes; diabetes
complications; hyperlipidemia/dyslipidemia; hypertension;
stroke/transient ischemic attack; congestive heart disease;
heart failure; peripheral arterial disease; atrial fibrillation;
angina; myocardial infarction; coronary artery operations;
deep vein thrombosis; depression; urinary incontinence; Par-
kinson’s disease; severe mental illness; drug abuse; epilepsy;
anxiety; anxiety symptoms; insomnia, fatigue, or other sleep
problems; migraine; headache; back/neck pain; and neuro-
pathic pain. Depression severity was measured as the maxi-
mum record in their history (mild, moderate, or severe), and
depression duration, defined as the years since first record of
a depression diagnosis or symptom.
The following covariates were measured as recorded in
the general practitioner’s records in both the 12 months
before the start and the end of the DEP: any fall, any fracture,
number of consultations, and any prescription for a selective
serotonin reuptake inhibitor (ATC N06AB), tricyclic antide-
pressant (ATC N06AA), or an antipsychotic (ATC N05A).
Smoking status (none, former, current), bodymass index (weight
(kg)/height (m2); <20, 20–24.9, 25–29.9, ≥30), and harmful
alcohol use (>49 units/week for men and >35 units/week for
women) were measured according to the latest record.
Statistical analyses
We used conditional logistic regression to estimate the
association between categorized DDDs (0, >0–29, 30–364,
365–1,459, or ≥1,460 DDDs) of benzodiazepines and Z-
drugs and dementia incidence. Odds ratios and 95% confi-
dence intervals were estimated without adjustment and then
separately adjusted for birth year, practice region (Scotland,
Northern Ireland, Wales, and 10 health regions of England),
and the aforementioned covariates.
To test the impact of covariate ascertainment timing, we
estimated 2 sets of models, first including covariates mea-
sured at the start of the DEP, and second including covariates
measured at the end of the DEP. We then estimated associa-
tions among new users and prevalent users compared with
nonusers in each case.
The impact of each covariate was measured by the change in
the log of the odds ratio induced by adding that covariate to a
model only including the exposure stratified into new and prev-
alent use (36). The impact of each covariate was compared
when it wasmeasured at the start or end of theDEP. Confidence
intervals were calculated by nonparametric bootstrapping.
Finally, to test whether associations between new use and
dementia incidence varied with the time between medication
initiation and dementia incidence, we stratified odds ratios
for any new prescription and total DDDs during the DEP by
time of initiation in 3 periods: 15–20, 10–15, or 5–10 years
before dementia (among those with at least 16, 11, and 6
years of up-to-standard data history, respectively). For these
analyses, we adjusted for covariates at the later of the interval
start date and the DEP start date.
Throughout, multiple imputation via chained equations were
used to impute missing values of body mass index, harmful
alcohol use, and smoking (37) (see Web Appendix for details
of imputation models). We used Stata, version 14.2 (StataCorp
LP, College Station, Texas) for all statistical analyses. Statistical
significance was determined using 2-tailed tests, with a prespe-
cified threshold ofP < 0.01.
RESULTS
Of 66,136 cases of dementia recorded in CPRD between 2006
and 2015, 40,770 met inclusion criteria and were matched to
283,933 control subjects (Web Figure 2). The median (interquar-
tile range) DEP was 7.1 (4.0–11.3) years; median age at index
date was 83 (78–87) years, and 63%werewomen (Table 1).
By definition, the proportion of patients with a history of each
clinical condition increased over the DEP (Web Table 2). For
example, up to the start of their DEP, 25,870 patients (8%) had a
diagnosis of anxiety and 21,347 (7%) had insomnia. By the end
of the DEP this had increased to 41,788 (13%) and 52,578
(16%), respectively. Case patients were more likely than control
subjects to have a history of cardiovascular disease and depres-
sion, and to visit their general practitionermore frequently.
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Among the case patients, 8,010 (20%) were ever prescribed
benzodiazepines and 3,130 (8%) were prescribed Z-drugs dur-
ing their DEP, compared with 52,017 (18%) and 19,163 (7%)
of the control subjects, respectively. The 5 most common pre-
scriptions were for temazepam (32% of all benzodiazepine or
Z-drug prescriptions), zopiclone (19%), diazepam (18%), nitra-
zepam (14%), and lorazepam (5%). SeeWeb Table 3 for details
of prescribing patterns.
Association between benzodiazepine prescriptions and
dementia incidence
The unadjusted odds ratio for dementia and any prescription
of a benzodiazepinewas 1.09 (95%CI: 1.06, 1.12), but there was
little suggestion of a dose-response relationship with the number
of DDDs (Table 2). Adjusting for covariates measured at the start
of the DEP led to an inverse association between benzodiaze-
pines and dementia (for≥4 years of DDDs, OR = 0.88, 95%CI:
0.82, 0.95).When adjusting for covariatesmeasured at the end of
the DEP, the inverse association appeared stronger (for any use,
OR = 0.81, 95%CI: 0.75, 0.87).
New versus prevalent users of benzodiazepines
Of those prescribed benzodiazepines, 37,303 patients (62%)
were new users during the DEP, whereas 22,724 (38%) were
prevalent users (Table 2). New users had shorter average expo-
sures to benzodiazepines during the DEP than prevalent users,
who represented most cases of chronic use. Among new users,
there was little evidence of an association between benzodiaze-
pines and dementia incidence when adjusted for covariates mea-
sured at the start of the DEP (hence, adjusted for factors recorded
before medication initiation; OR = 1.03, 95% CI: 1.00, 1.07),
but the negative association was still apparent among prevalent
users (OR = 0.91, 95% CI: 0.87, 0.95), for whom the start of the
DEP was after medication initiation. When adjusted for covari-
ates measured at the end of the DEP, a negative association was
seen for both new use (OR = 0.91, 95%CI: 0.88, 0.95) and prev-
alent use (OR = 0.85, 95%CI: 0.81, 0.89) of benzodiazepines.
Impact of each covariate
The number of physician consultations, anxiety, insomnia,
depression, and antidepressant prescriptions each substantially
modified the estimated association between benzodiazepine
use and dementia incidence when added to the conditional
logistic regression models, whereas other factors did not (Web
Figure 3 and Web Table 4). Covariates modified the associa-
tion more when measured at the end of the DEP; patterns were
similar for prevalent and incident use.
Proximity between exposure and outcome
New use of benzodiazepines was not significantly associ-
ated with an increased risk of dementia regardless of whether
the first prescription was 5–10, 10–15, or 15–20 years before
dementia (Table 3). Although estimates are imprecise, asso-
ciations did appear to increase with closer proximity between
exposure initiation and outcome.
Z-drug prescriptions and dementia
Of those prescribed Z-drugs, 18,704 (84%) patients were new
users during the DEP, while 3,589 (16%) patients had received
prescriptions during the DEP and additionally in the previous 12
months. There was a positive association between Z-drugs and
Table 1. Sociodemographics and Data History of Dementia Case Patients and Control Subjects in the United Kingdom, April 2006–July 2015
Characteristic
Dementia Case Patients
(n = 40,770)
Control Subjects
(n = 283,933)
No. % No. %
Womena 25,745 63.1 179,152 63.1
Age at index date, yearsa,b 82.6 (6.8) 82.6 (6.8)
Practice level index of multiple deprivation quintilea
1 (least deprived) 7,867 19.3 54,766 19.3
2 7,928 19.4 55,220 19.4
3 8,756 21.5 61,032 21.5
4 8,389 20.6 58,407 20.6
5 (most deprived) 7,830 19.2 54,508 19.2
Country
England 30,615 75.1 223,468 78.7
Northern Ireland 1,508 3.7 8,720 3.1
Scotland 5,024 12.3 25,793 9.1
Wales 3,623 8.9 25,952 9.1
Drug-exposure period lengtha,c, years 7.1 (4.0–11.3) 7.1 (4.0–11.3)
a Matching variables.
b Values are expressed asmean (standard deviation).
c Values are expressed asmedian (interquartile range).
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dementia incidence without adjusting for covariates. No asso-
ciation was observed when adjusting for covariates measured
at the start of the DEP, and evidence of a negative association
was observed when adjusting for covariates measured after
the DEP (Web Tables 5 and 6). The pattern of the impact of
individual covariates was almost identical for Z-drugs and
benzodiazepines, with depression, antidepressant use, physi-
cian consultations, anxiety, and insomnia having the greatest
impact on estimated associations (Web Figure 4 and Web
Table 7). As with benzodiazepines, this impact was up to 3 or
4 times greater when covariates were measured at the end of
the DEP compared with the start of the DEP and was consis-
tent for prevalent and new users of Z-drugs.
DISCUSSION
Associations between benzodiazepine and Z-drug prescrip-
tions and dementia incidence depend on the timing of covariate
ascertainment and whether prevalent or only new use is con-
sidered. When covariates were only measured before exposure,
associations were typically null or slightly positive. When co-
variates were included in the models that may have occurred
before or after initiation of drug exposure, associations were
typically negative. Taken together, our results suggest no causal
link between benzodiazepines or Z-drug use and later dementia
incidence, that any positive association is an artefact of either
inadequate control of confounding factors or protopathic bias,
and any negative association is the result of adjusting for colli-
ders in regressionmodels.
In every case, adjustment for depression, anxiety, antide-
pressant use, insomnia, fatigue, and number of recent physi-
cian visits had the most impact on our estimates. No other
covariate substantially affected the relationships in any analy-
sis. As well as being possible indications for benzodiazepines,
depression, anxiety, and sleep disturbance are known symp-
toms of dementia and are suspected risk factors (3). Therefore,
there are several equally plausible explanations for the observed
Table 2. Association Between Benzodiazepine Prescriptions and Dementia, by Defined Daily Doses, New or Prevalent Use, andWhen
CovariatesWereMeasured, in a Nested Case-Control Study in the United Kingdom, December 1988–July 2015
No. of Benzodiazepine DDDs During DEP No. of CasePatients
No. of Control
Subjects
Unadjusted Measured at Startof DEP
Measured at End
of DEP
OR 95%CI aORa 95%CI aORa 95%CI
All users
Any benzodiazepine prescription 8,010 52,017 1.09b 1.06, 1.12 0.99 0.96, 1.02 0.89b 0.86, 0.92
DDDs during DEP
0 32,760 231,916 1.00 Referent 1.00 Referent 1.00 Referent
0.1–29 3,949 25,390 1.10b 1.07, 1.14 1.02 0.99, 1.06 0.92b 0.89, 0.96
30–364 1,998 12,516 1.13b 1.08, 1.19 1.01 0.96, 1.06 0.88b 0.84, 0.93
365–1,459 1,143 7,775 1.04 0.98, 1.11 0.92 0.86, 0.98 0.84b 0.78, 0.89
≥1,460 920 6,336 1.03 0.96, 1.11 0.88b 0.82, 0.95 0.81b 0.75, 0.87
Users stratified by new and prevalent use
Any benzodiazepine prescription during
DEP
0 32,760 231,916 1.00 Referent 1.00 Referent 1.00 Referent
Any prescription by new users 5,058 32,245 1.11b 1.08, 1.15 1.03 1.00, 1.07 0.91b 0.88, 0.95
Any prescription by prevalent users 2,952 19,772 1.06b 1.02, 1.10 0.91b 0.87, 0.95 0.85b 0.81, 0.89
DDDs during DEP
None 32,760 231,916 1.00 Referent 1.00 Referent 1.00 Referent
Within new users
0.1–29 3,568 23,103 1.10b 1.06, 1.14 1.02 0.99, 1.07 0.92b 0.89, 0.96
30–364 1,135 6,987 1.15b 1.08, 1.23 1.05 0.98, 1.12 0.88b 0.82, 0.94
365–1,459 269 1,567 1.22b 1.07, 1.39 1.10 0.96, 1.25 0.94 0.82, 1.07
≥1,460 86 588 1.04 0.83, 1.30 0.96 0.76, 1.20 0.84 0.67, 1.05
Within prevalent users
0.1–29 381 2,287 1.18b 1.06, 1.32 1.00 0.89, 1.12 0.93 0.83, 1.04
30–364 863 5,529 1.10b 1.03, 1.19 0.97 0.90, 1.04 0.89b 0.83, 0.96
365–1,459 874 6,208 1.00 0.93, 1.07 0.87b 0.81, 0.94 0.81b 0.75, 0.87
≥1,460 834 5,748 1.03 0.96, 1.11 0.87b 0.81, 0.94 0.81b 0.75, 0.87
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; DDD, defined daily dose; DEP, drug exposure period; OR, odds ratio.
a Adjusted for all variables in Table 1 andWeb Table 2.
b P < 0.01.
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relationships between these variables in our study. Figure 1 illus-
trates confounding, reverse causation, colliding, and mediating
relationships. Panels A and B of Figure 1 show the importance of
controlling for neuropsychiatric symptoms; panels C andD illus-
trate the danger in doing this, because the record of neuropsychi-
atric symptoms may act as a collider or a mediator. Note that in
each case, neuropsychiatric symptomsmight equally be recorded
before or after themeasured exposure and so these scenarios can-
not be definitively distinguished theoretically or empirically.
Nevertheless, by varying the timing of covariate ascertain-
ment compared with the timing to treatment initiation, we can
place reasonable bounds on causal associations by considering
whether each analysis is more likely to under- or overestimate
it. For new users, the start of the DEP might be some time
before treatment initiation, and so controlling for covariates
measured up to this time risks residual confounding and over-
estimating associations. Covariates measured at the end of the
DEPmay have occurred after treatment and so including these
Table 3. Association Between NewBenzodiazepine Prescriptions and Dementia, According toWhen the NewPrescriptionWas Issued, in a
Nested Case-Control Study in the United Kingdom, December 1988–July 2015
No. of DDDs No. of Case Patients No. of Control Subjects
Unadjusted Adjusted for CovariatesMeasured at Start of DEP
OR 95%CI aORa 95%CI
New use initiated 15–20 years priorb
Benzodiazepine prescription
No 7,747 43,261 1.00 Referent 1.00 Referent
Yes 560 2,916 1.06 0.97, 1.17 0.98 0.89, 1.08
DDDs during DEP
0 7,747 43,261 1.00 Referent 1.00 Referent
0.1–29 283 1,646 0.96 0.84, 1.09 0.90 0.79, 1.02
30–364 201 863 1.27c 1.09, 1.49 1.16 0.99, 1.36
365–1,459 43 232 1.02 0.74, 1.42 0.91 0.65, 1.27
≥1,460 33 175 1.02 0.70, 1.48 0.97 0.66, 1.41
New use initiated 10–15 years priord
Benzodiazepine prescription
No 18,097 105,328 1.00 Referent 1.00 Referent
Yes 1,316 6,741 1.12c 1.05, 1.19 1.01 0.95, 1.08
DDDs during DEP
0 18,097 105,328 1.00 Referent 1.00 Referent
0.1–29 849 4,304 1.14c 1.05, 1.22 1.03 0.95, 1.11
30–364 322 1,756 1.05 0.93, 1.18 0.93 0.82, 1.05
365–1,459 107 464 1.32 1.06, 1.63 1.17 0.95, 1.45
≥1,460 38 217 0.99 0.70, 1.40 0.92 0.65, 1.30
New use initiated 5–10 years priore
Benzodiazepine prescription
No 31,471 191,614 1.00 Referent 1.00 Referent
Yes 2,564 13,636 1.14c 1.09, 1.19 1.03 0.99, 1.08
DDDs during DEP
0 31,471 191,614 1.00 Referent 1.00 Referent
0.1–29 1,904 10,289 1.12c 1.07, 1.18 1.03 0.98, 1.08
30–364 528 2,707 1.18c 1.08, 1.30 1.04 0.94, 1.14
365–1,459 117 568 1.23 1.01, 1.50 1.08 0.88, 1.32
≥1,460 15 72 1.26 0.72, 2.20 1.16 0.66, 2.02
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; DDD, defined daily dose; DEP, drug exposure period; OR, odds ratio.
a Adjusted for all variables in Table 1 andWeb Table 2.
b Including patients with≥16 years of up-to-standard data history before the index date.
cP < 0.01.
d Including patients with ≥11 years of up-to-standard data history before the index date. Start of period defined by the later of the start of the DEP
and 15 years before the index date.
e Including patients with ≥6 years of up-to-standard data history before the index date. Start of period defined by the later of the start of the DEP
and 10 years before the index date.
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risks underestimation. For prevalent users, anymeasured covar-
iate may have occurred after treatment initiation, hence under-
estimation is more likely, whereas univariable analyses and
those with short lag times are likely to lead to overestimation.
The key strengths of our study include the detailed evalua-
tion of the impact of varying study design parameters and use
of an exposure period up to 20 years before diagnosis of demen-
tia for a significant number of cases. Diagnosis of dementia in
CPRD has been validated with a positive predictive value of
95% (2). The available data allowed us to carefully consider the
roles of a wide range of potential covariates measured at differ-
ent points. Measurement of exposure was based on prescription
rather than use, but these are likely to be similar, particularly for
chronic users.
Substantively, our study updates and builds on the findings
of Imfeld et al. (18), who reported no significant association
with benzodiazepine or Z-drug use and risk of dementia, also
based on a case-control study nested within CPRD, although
using a period for case ascertainment that began before finan-
cial incentives for the accurate recording of dementia diagno-
ses in primary care in the United Kingdom. Gray et al. (17)
reported a small association among low users that was not
observed when the lag period was extended beyond 2 years,
again suggesting no causal link. Authors for a Swiss study
also reported no association between benzodiazepine prescrip-
tions and new dementia medication prescriptions, despite only
allowing a 2-year lag period (38).
Study design choicesmight explain previously reported posi-
tive associations between benzodiazepine use and dementia. In
2 studies that did not apply any lag between exposure and out-
come, causal effect likely was overestimated (14, 16). In a study
based on a Canadian insurance claims database, a significant
association was reported with a dose-response relationship
(15). Although they controlled for anxiety and sleep distur-
bance, the authors did not have any record of these indications
for most users, suggesting that the control of confounding fac-
tors was inadequate.
Inclusion of prevalent users in pharmacoepidemiologic stud-
ies is challenging. However, authors of previous studies exam-
ining benzodiazepine use and dementia incidence reported only
slightly smaller associations with prevalent use compared with
new use (14, 39).
In summary, we found no evidence that benzodiazepine or
Z-drug use is associated with risk of dementia. However,
because benzodiazepines have known adverse effects, including
falls and sedation, and lead to tolerance (6), prescribers should
continue to follow guidelines on avoiding or limiting their use.
Our study reinforces the challenges in estimating associa-
tions between long-term cumulative exposures and adverse
events with long latent or prodromal periods, particularly where
indications for the exposure are also prodromal symptoms of
the outcome. Nevertheless, these remain important questions
that observational studies provide almost the only opportunity
to answer, and so these challenges must be addressed. Investi-
gators should carefully consider the causal framework for
potential covariates, whenmeasured at different time points and
among prevalent and new users, and should be mindful that
prodromal periods for neurodegenerative diseases could be
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Figure 1. Directed acyclic graphs in a nested case-control study in the United Kingdom, December 1988–July 2015, illustrating theoretically plau-
sible relationships between psychiatric conditions, benzodiazepine prescription (exposure), neurodegenerative disease, and the record of psychi-
atric symptoms (measured covariate that might be caused by a primary neuropsychiatric condition or a latent neurodegenerative disease) and
dementia diagnosis (outcome). Solid outlines indicate observed variables. Dashed lines indicate false associations induced by omitted variable
bias: A) confounding by indication; B) reverse causation; and C) adjusting for a collider. D) In the case of a genuine relationship between benzodia-
zepines and dementia, “record of neuropsychiatric symptoms” after treatment initiationmay reflect a mediator of the relationship.
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extremely long. Given the inherent difficulty of measuring con-
founders and of separating confounding from mediating or col-
liding effects in these cases, the aim for observational studies
should not necessarily be to provide single unbiased effect esti-
mates, but such studies can provide robust upper or lower bounds
on effect sizes, depending on study design, that should be con-
sidered alongside other forms of evidence using, for example, a
triangulation framework to narrow the range of plausibly true
causal effects (40).
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